Sanofi Overcomes Zantac Troubles To Gain Share In US
Executive Summary
Sanofi Consumer Healthcare has been gaining share in the US OTC market since October 2020 after putting behind it long running Zantac troubles, according to business head Julie Van Ongevalle.
You may also be interested in...
Sanofi Eyes Using Zantac 360 Most-Recommended Ad Claim With Disclaimer Highlighting Ingredient
Industry self-regulation group’s appeals board agrees with investigative division’s finding Sanofi didn’t support Zantac 360 “#1 doctor recommended” ad claims. Board declines to consider whether “#1 doctor recommended H2 active ingredient” with “based on generic acid reducer recommendations” disclaimer is supported.
Q1 Consumer Health Earnings Preview: GSK, Sanofi And Bayer
Likely talking points when three of the biggest global consumer health players report Q1 results include: GSK's separation plan and the influence of a new major investor; Sanofi's program to divest over half of its OTC brands; and Bayer's ability to sustain higher sales of dietary supplements post-COVD-19.
Sanofi To Divest 60% Of Brands In Consumer Healthcare Overhaul
Sanofi will look to offload around 150 OTC brands as part of a radical overhaul of its Consumer Healthcare operation. The new head of the business Julie Van Ongevalle has unveiled a wide-ranging turnaround plan with the goal of transforming Sanofi into the OTC market leader.